M R Lichinitser - JoVE Visualize

Showing results (21-30 of 35) with videos related to

Pageof 4

Sort By:

Voprosy Onkologii|January 1, 1978

[Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer]M R Lichinitser, N I Perevodchikova, A M Garin, et al.

Voprosy Onkologii|January 1, 1987

[The use of aminoglutethimide (orimeten) in disseminated breast cancer]T M Nadezhdina, G V Vyshinskaia, M R Lichinitser, et al.

Antibiotiki|May 1, 1978

[Carminomycin study in breast cancer]M R Lichinitser, I V Assekritova, V A Gorbunova, et al.

Voprosy Onkologii|January 1, 1975

[Chemoradiation therapy of inoperable lung cancer]M S Starichkov, M M Nivinskaia, M B Bychkov, et al.

Terapevticheskii Arkhiv|January 1, 1986

[4-component chemotherapy and radiation therapy of breast cancer]A A Gritsaĭ, M R Lichinitser, G V Vyshinskaia, et al.

Voprosy Onkologii|January 1, 1988

[Biological effects of leakadin]A M Garin, M R Lichinitser, N V Dmitrieva, et al.

Breast Cancer Research and Treatment|June 30, 2005

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrantJ F R Robertson, A Howell, V A Gorbunova, et al.

Arkhiv Patologii|January 22, 2003

[Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas]E V Stepanova, T K Kharatishvili, M R Lichinitser, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesJ-J Body, I J Diel, M R Lichinitser, et al.

European Journal of Cancer (Oxford, England : 1990)|July 15, 2004

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancerI J Diel, J-J Body, M R Lichinitser, et al.

Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:

Pageof 4

Voprosy Onkologii|January 1, 1978

[Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer]M R Lichinitser, N I Perevodchikova, A M Garin, et al.

Voprosy Onkologii|January 1, 1987

[The use of aminoglutethimide (orimeten) in disseminated breast cancer]T M Nadezhdina, G V Vyshinskaia, M R Lichinitser, et al.

Antibiotiki|May 1, 1978

[Carminomycin study in breast cancer]M R Lichinitser, I V Assekritova, V A Gorbunova, et al.

Voprosy Onkologii|January 1, 1975

[Chemoradiation therapy of inoperable lung cancer]M S Starichkov, M M Nivinskaia, M B Bychkov, et al.

Terapevticheskii Arkhiv|January 1, 1986

[4-component chemotherapy and radiation therapy of breast cancer]A A Gritsaĭ, M R Lichinitser, G V Vyshinskaia, et al.

Voprosy Onkologii|January 1, 1988

[Biological effects of leakadin]A M Garin, M R Lichinitser, N V Dmitrieva, et al.

Breast Cancer Research and Treatment|June 30, 2005

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrantJ F R Robertson, A Howell, V A Gorbunova, et al.

Arkhiv Patologii|January 22, 2003

[Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas]E V Stepanova, T K Kharatishvili, M R Lichinitser, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesJ-J Body, I J Diel, M R Lichinitser, et al.

European Journal of Cancer (Oxford, England : 1990)|July 15, 2004

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancerI J Diel, J-J Body, M R Lichinitser, et al.

Pageof 4